Protagonist Therapeutics (PTGX) Insider Trading & Ownership $61.43 +4.44 (+7.79%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$61.06 -0.37 (-0.59%) As of 08/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Protagonist Therapeutics (NASDAQ:PTGX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage4.90%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$18.37M Get PTGX Insider Trade Alerts Want to know when executives and insiders are buying or selling Protagonist Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Insider Buying and Selling by Quarter Protagonist Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/25/2025Dinesh V Ph D PatelCEOSell10,415$54.78$570,533.70 7/23/2025Dinesh V Ph D PatelCEOSell17,520$54.79$959,920.80 7/22/2025Dinesh V Ph D PatelCEOSell22,065$55.05$1,214,678.25 7/21/2025Dinesh V Ph D PatelCEOSell12,859$54.86$705,444.74 6/10/2025Arturo Md MolinaInsiderSell10,000$57.03$570,300.00 4/22/2025Asif AliCFOSell1,756$46.00$80,776.00 3/17/2025William D WaddillDirectorSell4,000$54.25$217,000.00 3/13/2025Arturo Md MolinaInsiderSell30,514$55.74$1,700,850.36 3/12/2025Asif AliCFOSell24,903$58.73$1,462,553.19 2/19/2025Dinesh V Ph D PatelCEOSell5,359$38.18$204,606.62 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 11/27/2024Arturo Md MolinaInsiderSell26,000$44.70$1,162,200.00 11/25/2024Dinesh V Ph D PatelCEOSell78,520$46.96$3,687,299.20 11/25/2024Suneel GuptaInsiderSell103,437$46.04$4,762,239.48 11/15/2024Arturo Md MolinaInsiderSell1,906$40.98$78,107.88 9/11/2024Asif AliCFOSell14,203$44.49$631,891.47 9/10/2024William D WaddillDirectorSell8,000$45.00$360,000.00 (Data available from 1/1/2013 forward) PTGX Insider Trading Activity - Frequently Asked Questions Who is on Protagonist Therapeutics' Insider Roster? The list of insiders at Protagonist Therapeutics includes Arturo Md Molina, Asif Ali, Dinesh V Ph D Patel, Suneel Gupta, and William D Waddill. Learn more on insiders at PTGX. What percentage of Protagonist Therapeutics stock is owned by insiders? 4.90% of Protagonist Therapeutics stock is owned by insiders. Learn more on PTGX's insider holdings. Which Protagonist Therapeutics insiders have been selling company stock? The following insiders have sold PTGX shares in the last 24 months: Arturo Md Molina ($3,511,458.24), Asif Ali ($2,665,561.92), Dinesh V Ph D Patel ($10,230,483.31), Suneel Gupta ($4,887,239.48), and William D Waddill ($1,583,636.50). How much insider selling is happening at Protagonist Therapeutics? Insiders have sold a total of 510,914 Protagonist Therapeutics shares in the last 24 months for a total of $22,878,379.45 sold. Protagonist Therapeutics Key ExecutivesDr. Dinesh V. Patel Ph.D. (Age 67)CEO, President, Secretary & Director Compensation: $1.03MMr. Asif Ali (Age 50)Executive VP & Chief Financial Officer Compensation: $631.04k2 recent tradesDr. Suneel K. Gupta Ph.D. (Age 66)Chief Development Officer Compensation: $719.21kDr. Mark Smythe Ph.D. (Age 59)Founder & VP Technology Mr. Mohammad Masjedizadeh Ph.D.Executive VP & Chief Technical OfficerMr. Matthew M. Gosling (Age 53)Executive VP & General Counsel Ms. Carena SpiveyHead of HR & Senior VP of Human ResourcesDr. Ashok Bhandari Ph.D. (Age 60)Executive VP & Chief Drug Discovery and Preclinical Development Officer Mr. Carter J. King (Age 53)Executive Vice President of Business Development Ms. Abha BommireddiExecutive Vice President of Portfolio & Program Management More Insider Trading Tools from MarketBeat Related Companies Viatris Insider Trades Moderna Insider Trades BridgeBio Pharma Insider Trades Verona Pharma PLC American Depositary Share Insider Trades Elanco Animal Health Insider Trades Blueprint Medicines Insider Trades Roivant Sciences Insider Trades Grifols Insider Trades Revolution Medicines Insider Trades Rhythm Pharmaceuticals Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Reynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say BuyStrategy Insiders Buy In While Analysts Predict Big Upside This page (NASDAQ:PTGX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access